Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Randomised, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD1613 Following Multiple Ascending Dose Administration in Participants With Autosomal Dominant Polycystic Kidney Disease

NCT07228364 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07228364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07228364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Randomised, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD1613 Following Multiple Ascending Dose Administration in Participants With Autosomal Dominant Polycystic Kidney Disease
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Recruiting
Start date
November 10, 2025
Completion date
May 22, 2027
Enrollment
40 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal dominant polycystic kidney disease